TRIDENT

三叉戟

基本信息

  • 批准号:
    6291662
  • 负责人:
  • 金额:
    $ 45.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2003-03-31
  • 项目状态:
    已结题

项目摘要

Support for the purchase of an Argonaut(TM) Trident parallel synthesis instrument is requested. There currently is no significant capability of automated parallel synthesis available to synthetic chemists at UCI, and research productivity on a number of NIH-funded projects would be enhanced dramatically by the acquisition of such an instrument. The requested Trident would serve as the cornerstone of a larger core facility at UCI, which is being established in order to make state-of-the-art parallel synthesis equipment available to UCI researchers for the first time. Research projects of the major users that would explicitly benefit from the purchase of this instrument include: (a) Chamberlin, memory enhancers, potassium channel blockers, and selective inhibitors of protein phosphatases; (b) Feher, novel dendritic compounds with peptidic and carbohydrate functionalities on a silsesquioxane core; (c) Nowick, artificial beta-sheets as models for protein structure; (d) Overman, guanidine-containing alkaloids and intramolecular Heck reaction development; (e) Rychnovsky, anticancer tetrahydrofurans; (f) Shea, bioreceptor mimics via molecular imprinting; (g) Van Vranken, ditryptophan- and dityrosine-crosslinked peptides; and (h) Woerpel, new reactions of silacyclopropanes. Aside from the major user group there are many other NIH funded research groups who will make use of the facility. The nature of the instrument to be purchased is such that it can be most effectively run by, or under the supervision of, an experienced operator; therefore, an important component of this request is a commitment by the UCI School of Physical Sciences of a new PhD level staff position to oversee the facility operations. UCI provides long-term major funding for a number of thriving instrumentation facilities that support the research faculty in Chemistry, including NMR, mass spectroscopy, molecular modeling, Xray, electronics, and laser/spectroscopy facilities. Currently the annual commitment is over $500,000 to these facilities in eight salaries and operational support. Additional operational funding is obtained though charges to the grants and contracts of the user community. The parallel synthesis facility, in which the requested Trident(TM) will reside, will follow this very successful model.
要求支持购买Argonaut(TM)三叉戟平行合成仪器。目前,UCI的合成化学家还没有自动平行合成的重要能力,而美国国立卫生研究院资助的一些项目的研究生产力将通过获得这样的仪器而大大提高。所要求的三叉戟将作为UCI更大核心设施的基石,该设施的建立是为了首次向UCI研究人员提供最先进的平行合成设备。明显受益于购买该仪器的主要用户的研究项目包括:(a)张伯林、记忆增强剂、钾通道阻滞剂和蛋白磷酸酶选择性抑制剂;(b)在硅氧烷核上具有肽和碳水化合物功能的新型树突状化合物;(c) Nowick,人造β片作为蛋白质结构模型;(d) Overman,含胍生物碱和分子内Heck反应发展;(e) Rychnovsky,抗癌四氢呋喃;(f) Shea,通过分子印迹模拟生物受体;(g) Van Vranken、二色氨酸和二酪氨酸交联肽;(h) Woerpel,硅环丙烷的新反应。除了主要用户组之外,还有许多其他NIH资助的研究小组将使用该设施。所购仪器的性质是由经验丰富的操作人员最有效地操作或在其监督下操作;因此,这一要求的一个重要组成部分是UCI物理科学学院承诺提供一个新的博士级别的工作人员职位来监督设施的运营。UCI为支持化学研究的许多蓬勃发展的仪器设备提供长期的主要资金,包括核磁共振、质谱、分子建模、x射线、电子学和激光/光谱设备。目前,这些设施的年度承付额超过50万美元,包括8项薪金和业务支助。通过向用户社区的赠款和合同收费获得额外的业务资金。“三叉戟”(Trident, TM)的平行合成设施将遵循这一非常成功的模式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A RICHARD CHAMBERLIN其他文献

A RICHARD CHAMBERLIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A RICHARD CHAMBERLIN', 18)}}的其他基金

NEW SIGNALING PATHWAY PROBES BASED ON NATURAL TOXINS
基于天然毒素的新信号通路探针
  • 批准号:
    6181136
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
NEW SIGNALING PATHWAY PROBES BASED ON NATURAL TOXINS
基于天然毒素的新信号通路探针
  • 批准号:
    2602736
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
Control of PP1/PP2A Activity With Small Molecule Toxins
用小分子毒素控制 PP1/PP2A 活性
  • 批准号:
    6871233
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
Control of PP1/PP2A Activity With Small Molecule Toxins
用小分子毒素控制 PP1/PP2A 活性
  • 批准号:
    7218074
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
NEW SIGNALING PATHWAY PROBES BASED ON NATURAL TOXINS
基于天然毒素的新信号通路探针
  • 批准号:
    6386897
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
Control of PP1/PP2A Activity With Small Molecule Toxins
用小分子毒素控制 PP1/PP2A 活性
  • 批准号:
    7030245
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
NEW SIGNALING PATHWAY PROBES BASED ON NATURAL TOXINS
基于天然毒素的新信号通路探针
  • 批准号:
    6019426
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
Control of PP1/PP2A Activity With Small Molecule Toxins
用小分子毒素控制 PP1/PP2A 活性
  • 批准号:
    6777786
  • 财政年份:
    1998
  • 资助金额:
    $ 45.09万
  • 项目类别:
ENANTIOSELECTIVE SYNTHESIS OF MYO-INOSITOL DERIVATIVES
肌醇衍生物的对映选择性合成
  • 批准号:
    3305688
  • 财政年份:
    1992
  • 资助金额:
    $ 45.09万
  • 项目类别:
INTRODUCTION OF NON-NATURAL AMINO ACIDS INTO PROTEINS
将非天然氨基酸引入蛋白质中
  • 批准号:
    3301523
  • 财政年份:
    1991
  • 资助金额:
    $ 45.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了